Big Pharma
14 November 2025 In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.
13 November 2025
13 November 2025
10 November 2025
6 November 2025
Latest Features
Americas
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko.
More News
6 November 2025 Womble Bond Dickinson has expanded its West Coast footprint with the addition of a seasoned patent litigator, strengthening the firm’s life sciences capabilities amid rising IP disputes and rapid biotech innovation.
4 November 2025 Merck Serono has failed to convince a US appeals court to overturn a PTAB decision invalidating two dosing regimen patents for cladribine.
3 November 2025 With AI reshaping IP enforcement, the pharma giant’s IP head warns that only active guidance will stop the industry from lagging behind, reports Muireann Bolger.
31 October 2025 Rising patent litigation over rare disease treatments highlights the success of the Hatch-Waxman and Orphan Drug Acts, says John Cox at Barnes & Thornburg.
30 October 2025 Danish pharma giant sweetens offer for hot peptide therapeutics company, aiming to cement its market position amid an intensifying GLP-1 patent race.
27 October 2025 As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.
23 October 2025 Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee retention strategies to cross-border patent standards.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox